India city Mumbai covid-19 patient Coronavirus India city Mumbai

Cipla seeks approval to launch experimental coronavirus drug in India

Reading now: 302
www.livemint.com

Domestic pharma major Cipla has sought approval from Indian regulators to launch experimental coronavirus drug favipiravir in India for treatment of Covid-19 patients.

Under the auspices of Indian Council of Medical Research or ICMR, Cipla will conduct a limited trial prior to marketing the product as Ciplenza.

Mumbai-based Glenmark Pharmaceuticals on Thursday said it has received approval from the Drug Controller General of India to conduct clinical trials of antiviral drug favipiravir on coronavirus patients.

Glenmark said it has received approval for conducting the trial on mild to moderate patients. Globally many drugs are under clinical trials on coronavirus patients to establish their efficacy against Covid-19.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA